Johnson & Johnson has reported two-year results from the Phase 3 ICONIC-TOTAL study showing sustained improvements in skin clearance among adults and adolescents with plaque psoriasis affecting difficult-to-treat, high-impact areas.

The findings, presented as a late-breaking oral presentation at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, evaluated patients aged 12 years and older with at least moderate psoriasis involving high-impact sites. The data extend through Week 112 and assess outcomes across areas including the scalp, genital region, hands and feet, as well as the nails.

Icotrokinra, marketed by Johnson & Johnson as ICOTYDE, is an oral peptide designed to selectively block the interleukin-23 (IL-23) receptor. The company describes it as the first targeted oral peptide to inhibit the receptor.

Among patients receiving icotrokinra, the proportion achieving clear or almost clear skin, defined as an Investigator’s Global Assessment (IGA) score of 0 or 1, increased over the course of treatment. The response rate was 57% at Week 16, rising to 67% at Week 24 and 70% at Week 112.

The study also reported site-specific clearance at Week 112. Sixty percent of patients with scalp psoriasis achieved a scalp-specific IGA score of 0, indicating complete clearance at the site. Among patients with genital psoriasis, 89% achieved a score of 0 on the Physician’s Global Assessment of Genitalia. For patients with psoriasis involving the hands and/or feet, 63% achieved a hand-and-foot PGA score of 0.

Nail disease also showed progressive improvement. Mean improvement from baseline in the modified Nail Psoriasis Severity Index increased from 33% at Week 16 to 62% at Week 52 and 71% at Week 112.

“These robust two-year data validate that ICOTYDE provides enduring skin clearance with a favorable safety profile,” says Richard B. Warren, MD, PhD, professor of dermatology at the University of Manchester.

Warren noted that psoriasis affecting areas such as the scalp, genitals, hands, feet and nails can have a disproportionate effect on patients’ daily lives, even when the overall area of skin affected is relatively limited.

Johnson & Johnson said the safety findings observed through Week 112 remained consistent with the established safety profile for icotrokinra. The company reported that no new safety signals were identified during the two-year follow-up period.

“Availability of long-term data are vital for informing the treatment of plaque psoriasis including particularly challenging areas of the body where conventional treatments may fall short,” says David M. Lee, MD, PhD, global immunology therapeutic area head at Johnson & Johnson. He adds that the longer-term results provide physicians with additional clinical data on the durability of responses in patients with psoriasis affecting high-impact body sites.

The ICONIC-TOTAL findings add to the longer-term clinical evidence being generated for icotrokinra as Johnson & Johnson evaluates the oral therapy across plaque psoriasis populations and disease presentations.